Related Experiment Videos
Carisoprodol withdrawal syndrome
Roy R Reeves1, John J Beddingfield, James E Mack
1G.V. (Sonny) Montgomery VA Medical Center, School of Medicine, University of Mississippi, Jackson, Mississippi, USA. roy.reeves@med.va.gov
Pharmacotherapy
|December 9, 2004
Summary
This case study documents the first known carisoprodol withdrawal syndrome, characterized by severe anxiety and hallucinations after abrupt cessation. The findings highlight potential abuse and addiction risks associated with this muscle relaxant.
Area of Science:
- Pharmacology
- Neuroscience
- Clinical Medicine
Background:
- Opioid analgesics like hydrocodone are commonly prescribed for chronic pain.
- Muscle relaxants such as carisoprodol are sometimes used as alternatives or adjuncts in pain management.
- Patient presented with a history of chronic back and shoulder pain, previously treated with hydrocodone.
Observation:
- A patient developed severe withdrawal symptoms including anxiety, tremors, insomnia, and hallucinations after abruptly stopping high-dose carisoprodol use.
- Symptoms emerged within 48 hours of cessation and peaked on the fourth day.
- The patient required pharmacological intervention with olanzapine and lorazepam for symptom management.
Findings:
- This is the first documented case of a carisoprodol withdrawal syndrome.
- The withdrawal symptoms are hypothesized to be due to the accumulation of meprobamate, the active metabolite of carisoprodol.
- High-dose carisoprodol consumption (≥10,500 mg/day) preceded the abrupt cessation and subsequent withdrawal.
Implications:
- Clinicians must be aware of the potential for carisoprodol abuse, addiction, and subsequent withdrawal.
- The findings suggest that carisoprodol may warrant classification as a controlled substance due to its abuse potential.
- Further research into the pharmacokinetics and pharmacodynamics of carisoprodol and its metabolite, meprobamate, is recommended.